Our Approach

Botulinum neurotoxins have been shown to improve symptoms in depressed patients. Object Pharma is developing a unique botulinum neurotoxin, different than currently marketed products, for treatment of depression and other mental health disorders.

The problem:

Depression is among the most common mental disorders and is a leading cause of disability, affecting over 280 million people worldwide. Current treatments are inadequate. “…Up to 50% of individuals with major depressive disorder (MDD) do not recover after two antidepressant medication trials…” § Estimated US economic costs due to major depressive disorder exceed $327 billion § Nearly 65% of treated patients require better, more-effective alternatives Physicians are desperate for effective treatment innovations.

$327B

Estimated US economic costs due to major depressive disorder

65%

of treated patients require better, more-effective alternatives

Physicians are desperate for effective treatment innovations.

The solution:

OP01 is a unique botulinum neurotoxin that is different than other marketed neurotoxin products. Object Pharma is developing OP01 exclusively for the treatment of mental health disorders.

Our first indication is major depressive disorder.

  • Several clinical studies have shown that botulinum  neurotoxin injections can reduce symptoms of  depression.
  • It is believed that Botulinum neurotoxin injections calm negative emotional proprioceptive feedback from the face to the brain which influences the experience of happiness or anger, and thus reduce depressive symptoms.